| Biological Sciences | 2021-2025 | 279 | US 58 | 99.72 |
| Cancer Research | Lifetime | 583 | US 308 | 96.18 |
| Cell Biology | Lifetime | 681 | US 377 | 95.93 |
| Hepatology | Lifetime | 797 | US 296 | 84.10 |
| Molecular Biology | 2021-2025 | 251 | US 64 | 98.89 |
| Cell Biology | 2021-2025 | 14 | US 3 | 98.19 |
| Cancer Research | 2021-2025 | 87 | US 33 | 96.10 |
| Oncology | 2021-2025 | 475 | US 207 | 93.91 |
| Immunology | 2021-2025 | 363 | US 129 | 90.35 |
| Surgery | 2021-2025 | 983 | US 379 | 90.80 |
| Pulmonary and Respiratory Medicine | 2021-2025 | 901 | US 330 | 87.73 |
| Pathology and Forensic Medicine | 2021-2025 | 397 | US 133 | 84.55 |
| Hepatology | 2021-2025 | 308 | US 83 | 77.82 |
| RNA modifications and cancer | Lifetime | 947 | US 452 | 98.28 |
| Liver physiology and pathology | Lifetime | 313 | US 117 | 97.32 |
| Cancer-related gene regulation | Lifetime | 890 | US 385 | 96.09 |
| Ferroptosis and cancer prognosis | Lifetime | 566 | US 136 | 94.56 |
| PI3K/AKT/mTOR signaling in cancer | Lifetime | 482 | US 271 | 96.43 |
| Cancer Mechanisms and Therapy | Lifetime | 461 | US 200 | 95.46 |
| Hippo pathway signaling and YAP/TAZ | Lifetime | 242 | US 111 | 95.26 |
| Wnt/β-catenin signaling in development and cancer | Lifetime | 525 | US 226 | 94.73 |
| RNA modifications and cancer | 2021-2025 | 295 | US 51 | 97.29 |
| Hippo pathway signaling and YAP/TAZ | 2021-2025 | 22 | US 6 | 94.24 |
| Cancer, Lipids, and Metabolism | 2021-2025 | 232 | US 58 | 93.46 |
| Cancer, Hypoxia, and Metabolism | 2021-2025 | 395 | US 98 | 91.81 |
| Ferroptosis and cancer prognosis | 2021-2025 | 511 | US 45 | 93.50 |
| Liver physiology and pathology | 2021-2025 | 94 | US 17 | 90.98 |
| RNA Research and Splicing | 2021-2025 | 607 | US 206 | 90.34 |
| Wnt/β-catenin signaling in development and cancer | 2021-2025 | 58 | US 15 | 86.83 |
| Cancer-related gene regulation | 2021-2025 | 376 | US 65 | 87.19 |
| PI3K/AKT/mTOR signaling in cancer | 2021-2025 | 174 | US 79 | 84.06 |
| Lipid metabolism and biosynthesis | 2021-2025 | 322 | US 71 | 79.52 |
| Cancer Mechanisms and Therapy | 2021-2025 | 700 | US 91 | 75.87 |
| Cancer-related Molecular Pathways | 2021-2025 | 918 | US 288 | 72.16 |
| Cytokine Signaling Pathways and Interactions | 2021-2025 | 969 | US 180 | 66.28 |
| Cholesterol and Lipid Metabolism | 2021-2025 | 456 | US 93 | 65.43 |
| Caveolin-1 and cellular processes | 2021-2025 | 135 | US 34 | 63.16 |
| Peroxisome Proliferator-Activated Receptors | 2021-2025 | 732 | US 132 | 63.23 |
| Kruppel-like factors research | 2021-2025 | 533 | US 112 | 61.06 |
